- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03337139
FitLink: Improving Weight Loss Maintenance by Using Digital Data to Provide Support and Accountability
December 10, 2020 updated by: Meghan Butryn, Drexel University
Improving Weight Loss Maintenance by Using Digital Data Sharing to Provide Responsive Support and Accountability
Most adults in the U.S. are overweight or obese and find maintenance of weight loss difficult.
This study is designed to aid in the development of a lifestyle modification program that can facilitate weight loss maintenance, without requiring long-term visits to a clinic for maintenance treatment.
Study Overview
Status
Completed
Conditions
Detailed Description
In a lifestyle modification program, contact with an interventionist (e.g., weight loss coach) creates a sense of supportive accountability that can facilitate behavior change and weight loss.
Sustaining a strong sense of supportive accountability after face-to-face intervention contact ends has the potential to improve outcomes during the notoriously difficult weight loss maintenance period.
One innovative way of facilitating supportive accountability is providing participants with digital tools that objectively measure weight and physical activity and track food intake in real-time, making the data from those tools automatically and continuously available to coaches, and designing the timing and content of intervention contacts such that they are responsive to the shared data.
Although tools that allow for data sharing from sensors and Internet-based applications are readily available, the ways in which they are integrated into intervention contacts in a lifestyle modification program are not yet optimized, and research has not systematically evaluated the effect of data sharing on behavior.
Overweight and obese participants (n = 90) will be recruited from the community for a small randomized controlled trial in order to test the feasibility, acceptability, efficacy, and mechanisms of action of a lifestyle modification intervention enhanced with data sharing.
In weeks 1-12 of the program (i.e., Phase I), all participants will attend 12 weekly, face-to-face, group-based behavioral treatment sessions to induce weight loss.
Participants will be provided with a wireless body weight scale, physical activity sensor, and digital food record app and instructed to use them daily use for self-monitoring purposes.
In Phase II (weeks 13-52), participants will be randomly assigned to the standard (LM) or enhanced version of remote lifestyle modification (LM+SHARE).
Neither condition will have face-to-face intervention contact during Phase II; remote intervention contact will consist of brief phone calls and text messages provided by the participant's coach.
Participants in both conditions will be prescribed continued daily use of the three self-monitoring devices.
In the standard LM condition, no digital data from these devices will be directly shared with coaches; intervention encounters will be informed only by the infrequent, delayed self-report of participants (which is the current standard of long-term obesity care), and timing of text messages will be fixed.
In LM+SHARE, the digital tools will automatically and continuously transmit body weight, physical activity, and food record data to the coach.
In LM+SHARE, supportive accountability will be enhanced in three ways: 1) participants will receive automated alerts after coaches view their data, 2) timing of personalized text messages from coaches will be responsive to clinically notable change in weight, physical activity, calorie intake, or use of scale, physical activity sensor, or food record tool, and 3) content of the text messages and phone calls will be informed by the digital data the coach has viewed, as well as the expectation that the coach will continue viewing data in order to provide ongoing support.
Assessments will be completed at 0, 12, 26, and 52 weeks.
Study Type
Interventional
Enrollment (Actual)
87
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Drexel University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged 18-70 years with a BMI of 25-45 kg/m2 and weight <160 kg
- Access to a smartphone
- Satisfactory completion of all enrollment procedures
- Ability to engage in physical activity (i.e. can walk at least 2 blocks without stopping for rest)
Exclusion Criteria:
Medical condition (i.e. acute coronary syndrome, type 1 diabetes, renal failure) or psychiatric condition (i.e. active substance abuse, eating disorder) that may:
- Pose a risk to the participant during the intervention
- Cause a change in weight
- Limit ability to comply with the behavioral recommendations of the program
- Pregnant or planning pregnancy in the next 1 year
- Planned move out of the Philadelphia area during the data collection period
- Use of a pacemaker (incompatible with wireless scale technology)
- Recently began or changed the dosage of a medication that can cause significant change in weight
- History of bariatric surgery
- Weight loss of > 10% in the previous 3 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Lifestyle Modification
Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on self-report.
|
Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session).
Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet.
Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
Individual, monthly, brief phone calls with coach and weekly text messages.
The content of these calls and messages will be determined by participant self-report.
Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
|
|
Experimental: Lifestyle Modification + Share
Three months of standard, group-based behavioral treatment for weight loss and nine months of remote individual behavioral treatment based on digital data shared with clinicians.
|
Group-based behavioral treatment for weight loss, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session).
Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
Participants will be asked to utilize digital monitoring devices for physical activity, weight, and diet.
Coaches will not have access to the digital data that participants provide on physical activity, weight, and diet monitoring devices.
Individual, monthly, brief phone calls with coach and weekly text messages.
The content of these calls and messages will be determined by the digital data that has been shared with the coach from physical activity, weight, and diet monitoring devices.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Weight
Time Frame: 0, 13, 26, 52 weeks
|
Objectively measured in the research clinic at each time point on a scale.
Reported as weight change in kg, where negative numbers reflect weight loss and positive numbers reflect weight gain.
|
0, 13, 26, 52 weeks
|
|
Change in Physical Activity
Time Frame: 13, 52 weeks
|
Objectively measured using wGT3X-BT accelerometers from Actigraph.
Minutes/week of moderate-to-vigorous physical activity (MVPA).
|
13, 52 weeks
|
|
Number of Participants Retained
Time Frame: 26, 52 weeks
|
Feasibility and acceptability metric of retention.
|
26, 52 weeks
|
|
Number of Completed Treatment Contacts
Time Frame: 52 weeks
|
Feasibility and acceptability metric of completed treatment contacts (phone calls and text messages).
|
52 weeks
|
|
Treatment Acceptability Questionnaire (TAQ)
Time Frame: 52 weeks
|
Feasibility and acceptability metric of scores on the TAQ.
Items on the TAQ consisted of 11 questions on a 7 point Likert scale asking about helpfulness and acceptability of treatment components.
Items are summed to yield a total score that can range from 11-77 with higher numbers indicated higher acceptability.
|
52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-monitoring Engagement
Time Frame: 13-52 weeks
|
Use of digital devices; percent of days during which weight, food, and steps were counted in Phase II.
Percent calculated for each group (LM vs. LM+Share) and not for individual participants.
We determined percent to be the metric that would be most easily interpreted and it accounted for any possible variability in total number of days of observations.
|
13-52 weeks
|
|
Perceived Accountability
Time Frame: 52 weeks
|
Change in "Perceptions of Accountability" subscale of the Supportive Accountability Scale.
The measure used was a 10-item scale on which participants rated the extent to which they agreed with statements on a 7-point likert scale.
A total score was generated by summing scores from individual items.
Total scores ranged from 10-70 with higher scorings indicating higher perceived accountability.
The outcome measure reported here is the change in total score on this measure (decrease) across Phase II where a negative score reflects a decrease in perceived accountability.
|
52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Meghan L Butryn, Ph.D., Drexel University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Butryn ML, Martinelli MK, Crane NT, Godfrey K, Roberts SR, Zhang F, Forman EM. Counselor Surveillance of Digital Self-Monitoring Data: A Pilot Randomized Controlled Trial. Obesity (Silver Spring). 2020 Dec;28(12):2339-2346. doi: 10.1002/oby.23015. Epub 2020 Oct 23.
- Schumacher LM, Martinelli MK, Convertino AD, Forman EM, Butryn ML. Weight-Related Information Avoidance Prospectively Predicts Poorer Self-Monitoring and Engagement in a Behavioral Weight Loss Intervention. Ann Behav Med. 2021 Mar 16;55(2):103-111. doi: 10.1093/abm/kaaa034.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 17, 2017
Primary Completion (Actual)
May 31, 2019
Study Completion (Actual)
May 31, 2019
Study Registration Dates
First Submitted
November 7, 2017
First Submitted That Met QC Criteria
November 7, 2017
First Posted (Actual)
November 8, 2017
Study Record Updates
Last Update Posted (Actual)
January 5, 2021
Last Update Submitted That Met QC Criteria
December 10, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1611004954
- R21DK112741 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Gold Standard Behavior Therapy for Weight Loss
-
Drexel UniversityCompletedObesity | Overweight | Weight LossUnited States
-
Drexel UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Yale...CompletedBinge-Eating Disorder | Weight Loss | Binge Eating | Eating DisorderUnited States
-
Drexel UniversityCompletedObesity | Overweight | Weight LossUnited States
-
University of PennsylvaniaNational Heart, Lung, and Blood Institute (NHLBI)CompletedObesity | Cardiovascular Disease | Major Depressive Disorder | Dysthymic DisorderUnited States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
University of VermontCompletedObesity | Weight Loss | Diet TherapyUnited States
-
University of Massachusetts, WorcesterNational Institute of Mental Health (NIMH)CompletedDepression | ObesityUnited States
-
Noom Inc.CompletedObesity | Weight Loss | Overweight and Obesity | Self Efficacy | Behavior, Health | Behavior, EatingUnited States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruiting
-
The University of Texas Health Science Center,...Not yet recruiting